This site uses cookies for technical purposes as specified in the cookie policy.
If you want to learn more or opt out of all or some cookies, see the cookie policy.
By closing the banner or continuing to browse, you consent to the use of cookies.
Scientific Insights
Projects
Peripheral and spinal nervous tissue, subjected to recurrent and/or chronic neuroinflammatory conditions of different origin, loses its capacity to synthesize Palmitoylethanolamide, thereby increasing the risk of inflammatory pain and, in cases of injury and/or somatosensory system dysfunction, can result in the gradual transformation of inflammatory pain into neuropathic pain.
In such cases it is of great importance to counteract the activation process of non neuronal cells (not only mast cells at the level of sensory endings and/or endoneural compartment but also microglia at the spinal level) cells who normal act to ensure a homeodynamic balance of nervous tissue.
Scientific evidence has shown that the patented and body-usable form of Palmitoylethanolamide (micronized and ultra-micronized) contributes to the physiological maintenance of nociceptive function at the musculoskeletal level and, in particular, in connective tissue.
Bibliografia
Aloe L. et al. A proposed autacoid mechanism controllino mastocyte behaviour. Agents Actions.1993
Del Giorno R. et al. Palmitoylethanolamide in Fibromyalgia: Results from Prospective and Retrospective Observational Studies. Pain Ther. 2015
Fusco R. et al. Effect of a new formulation of micronized and ultramicronized N-palmitoylethanolamine in a tibia fracture mouse model of complex regional pain syndrome.PLoS One. 2017
Littlejohn G. Neurogenic neuroinflammation in fibromyalgia and complex regional pain syndrome. Nat Rev Rheumatol. 2015
Paladini A. et al. Palmitoylethanolamide, a special food for medical purposes, in the treatment of chronic pain: a pooled data meta-analysis. Pain Physician. 2016
Petrosino S. et al. Oral Ultramicronized Palmitoylethanolamide: Plasma and Tissue Levels and Spinal Anti-hyperalgesic Effect. Frontiers in Pharmacology. 2018
Petrosino S. et al. Palmitoylethanolamide: A Nutritional Approach to Keep Neuroinflammation within Physiological Boundaries. A Systematic Review. Int J Mol Sci. 2020
Schweiger V. et al. Ultramicronized Palmitoylethanolamide (um-PEA) as add-on Treatment in Fibromyalgia Syndrome (FMS): Retrospective Observational Study on 407 Patients. CNS Neurol Disord Drug Targets. 2019
Skaper SD. et al. Microglia and mast cells: two tracks on the road to neuroinflammation. FASEB J. 2012
The access to the web site and to its content is only for personal use and purposes (i.e. for personal information, research or study).
Without prejudice to any right, faculty or authority of third parties, in case of prohibited conduct Epitech Group SpA shall reserve the right to act according to the law.